Dicerna shares rocket up on a $15M-plus-stock deal to settle Alnylam claims — will deals follow?
Shares of Dicerna soared more than 30% Friday afternoon after the biotech announced that it had settled a nasty lawsuit with rival Alnylam over …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
